CTOs on the Move

MDinteractive

www.mdinteractive.com

 
MDinteractive is a Sudbury, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

HealthServe Medical Group

HealthServe is a progressive organization designed to infuse our clients with the technology and services that will enable them to flourish in today's demanding business environment. Our broad range of experience is organized into three dynamic service

Medical Specialists of the Palm Beaches

Medical Specialists of the Palm Beaches is a primary care focused, multi-specialty physician group practice serving Palm Beach and Broward counties in Florida. They offer primary care, cardiology, neurology, hematology/oncology, concierge medicine, and...

Novitas Solutions

Novitas Solutions is a Camp Hill, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Mount Evans Hospice

Mount Evans Hospice is a Evergreen, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Allergen Research

Aimmune is a clinical-stage biopharmaceutical company advancing a new therapeutic approach, including the development of proprietary product candidates, for the treatment of peanut and other food allergies. Our mission is to improve the lives of people with food allergies by developing and commercializing proprietary desensitization therapies that safely and reliably protect them from accidental exposure to food allergens. We aim to address food allergies by providing a treatment option that goes beyond the current protocols of avoiding exposure to food allergens and carrying epinephrine for administration in case of accidental exposure. Our CODIT™ system is based on extensive independent scientific research demonstrating that most patients with food allergies can become desensitized to the allergens, or proteins, in a particular food through the oral administration of gradually increasing amounts of the allergens. In oral immunotherapy (OIT), a very small amount of an allergen is administered on a daily basis and then regularly increased until desensitization to a certain amount of the allergen has been achieved. We plan to develop and commercialize standardized, pharmaceutical-grade food allergens for our CODIT™ (characterized oral desensitization immunotherapy) system, our system for OIT. Our lead product candidate, AR101, is a standardized, complex mixture of 13 naturally occurring proteins and pharmaceutical-grade ingredients that, with the CODIT system of gradual, controlled updosing and ongoing maintenance dosing, has obtained meaningful desensitization to peanut allergens in our initial clinical studies.